Imatinib mesylate, Tyrosine kinase inhibitor (ab142070)
- Datasheet
- References
Overview
-
Product name
Imatinib mesylate, Tyrosine kinase inhibitor -
Description
Potent, selective tyrosine kinase inhibitor -
Alternative names
- 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-phenyl]benzamide methanesulfonate
- CGP 57148
- CGP 57148B
see all -
Biological description
Potent, selective inhibitor of tyrosine kinases v-Abl (IC50 = 38 nM), PDGFR and c-kit. Potent inhibitor of the Bcr-Abl tyrosine kinase created by the Philadelphia chromosome abnormality found in CML. Decreases proliferation and enhances apoptosis in leukemias CML and ALL.
-
Purity
> 98% -
CAS Number
220127-57-1 -
Chemical structure
Properties
-
Chemical name
4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide mesylate -
Molecular weight
589.73 -
Molecular formula
C29H31N7O.CH4SO3 -
PubChem identifier
123596 -
Storage instructions
Shipped at Room Temperature. Store at -20°C. Store under desiccating conditions. -
Solubility overview
Soluble in water to 100 mM and in DMSO to 100 mM -
Handling
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
SMILES
CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5.CS(=O)(=O)O -
Source
Synthetic
References
This product has been referenced in:
- Corbin AS et al. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 101:4611-4 (2003). Read more (PubMed: 12576318) »
- Krystal GW Mechanisms of resistance to imatinib (STI571) and prospects for combination with conventional chemotherapeutic agents. Drug Resist Updat 4:16-21 (2001). Read more (PubMed: 11512148) »
- Heinrich MC et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96:925-32 (2000). Read more (PubMed: 10910906) »
- Buchdunger E et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 56:100-4 (1996). Read more (PubMed: 8548747) »
